Your browser is outdated! Try to open this webpage in another browser.
Aller au contenu

LISI

LISI

The LISI group is one of the world leaders in fasteners and assembly components in the aerospace and automotive industries, and has operated in the healthcare sector since 2007. LISI is an acronym for Link Solutions for Industry.

As at April 19, 2022
Stake in LISI
14.4 %
Investment date
1977

Peugeot Invest's investment

The Peugeot family has been a shareholder of Compagnie Industrielle de Delle (CID), LISI’s main shareholder, since 1977. In 1996, Peugeot Invest received a 25% interest in CID as a transfer from another Peugeot family group company.

In 2002, Peugeot Invest took a direct 5% holding in LISI. At 31 December 2022, the Peugeot Invest group (via its wholly owned subsidiary Peugeot Invest Assets) directly and indirectly owned 19% of LISI. After the planned reorganisations, Peugeot Invest may no longer own any shares in CID at the end of the first half of 2023 (see section 4.3).

Peugeot Invest Assets has signed an agreement with CID’s main shareholders regarding liquidity for CID shares.

The Net Asset Value of the shareholding is based on the share price at 31 December 2022. LISI and CID are accounted for under the equity method.

Christian Peugeot, Thierry Peugeot and Xavier Peugeot are directors of CID, and CID has a seat on LISI’s Board of Directors. Peugeot Invest Assets, represented by Christian Peugeot, has a seat on LISI’s Board of Directors and is a member of its Strategy Committee. Marie-Hélène Peugeot-Roncoroni is a director of LISI and chair of its Remuneration and Appointments Committee.

In 2022

In 2022, revenue at LISI Aerospace (50% of the group’s sales) rose 19% (at constant scope and exchange rates) to €717 million. This division’s performance reflected increased production of singleaisle aircraft and the upturn in global air traffic, which had recovered to 86% of pre-Covid levels by the end of 2022.

LISI’s Fasteners business saw revenue growth of 30% in 2022, driven by commercial success in the United States and the strong dollar, while its Structural Components business maintained its recovery with growth of 26%. This division continued to be the main contributor to LISI’s underlying operating profit (56% of the group total).

LISI Automotive (39% of group sales) saw its potential market grow by 3.5% but stood out with sales of €558 million, representing growth of 11% (at constant scope and exchange rates), and so it continued to gain market share. Order intake rose sharply for new products (an increase of 22.8%), and was driven in particular by electromobility markets.

LISI Medical (11% of the group’s sales) generated revenue of €151 million, up 15% (at constant scope and exchange rates). Its sales growth was buoyed by higher production levels arising from a multi-year contract worth more than $170, won at the start of the year from a major player in minimally invasive surgery.

Overall, LISI’s revenue amounted to €1,425 million, an increase of 22%. Underlying operating margin was 6.3% (up 0.6 points). LISI’s free cash flow was €19 million and its net debt ended the year at €292 million.

Key figures

Turnover 2022
1.4 bn

Shareholding structure

54.8 %
CID
5.8 %
VMC
5.1 %
Peugeot Invest
2.2 %
Treasury shares
32.2 %
Free-float and others